CLINICAL USE

Mild-moderate dementia in Alzheimer’s diseaseIdiopathic Parkinson’s disease

DOSE IN NORMAL RENAL FUNCTION

3–6 mg twice daily (initially 1.5 mg twice daily)

PHARMACOKINETICS

  • Molecular weight                           :250.3 (400.4 as hydrogen tartrate)
  • %Protein binding                           :40
  • %Excreted unchanged in urine     : 0 (>90 as pharmacologically inactive metabolites)
  • Volume of distribution (L/kg)       :1.8–2.7
  • half-life – normal/ESRD (hrs)      :1/–

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Start at a low dose and gradually increase
  • 10 to 20     : Start at a low dose and gradually increase
  • <10           : Start at a low dose and gradually increase

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Likely dialysability. Dose as in GFR <10 mL/min
  • HD                     :Likely dialysability. Dose as in GFR <10 mL/min
  • HDF/high flux   :Likely dialysability. Dose as in GFR <10 mL/min
  • CAV/VVHD      :Likely dialysability. Dose as in GFR=10-20 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsMuscle relaxants: enhances effect of suxamethonium; antagonises effect of non-depolarising muscle relaxants

    ADMINISTRATION

    Reconstition

    –

    Route

    Oral

    Rate of Administration

    –

    Comments

    –

    OTHER INFORMATION

    Administer with food. Swallow whole .

    • Tags:

    Related News

    ffddfd

    Hyperlipidemia